Modeling of microRNA-derived disease network repurposes methotrexate for the prevention and therapy of abdominal aortic aneurysm in mice

Yicong Shen, Yuanxu Gao, Jiangcheng Shi, Zhou Huang, Rongbo Dai, Yi Fu, Yuan Zhou, Wei Kong, Qinghua CuibioRxiv 2021 · DOI

TL;DR

This study leverages network medicine and microRNA (miRNA) associations to build a comprehensive disease network, revealing that abdominal aortic aneurysm (AAA) shares strong similarities with autoimmune diseases. This insight led to the successful repurposing of methotrexate, an autoimmune drug, for preventing and treating AAA in mouse models.

What Problem Does This Paper Address?

Abdominal aortic aneurysm (AAA) is a dangerous vascular disease with no effective drug therapies, leaving surgery as the primary treatment option. The development of new drugs is costly and time-consuming. This paper addresses the urgent need for novel, non-invasive therapeutic strategies for AAA by exploring drug repurposing, specifically by identifying potential drug candidates through an analysis of disease relationships.

Methods

The researchers developed a novel algorithm to quantify disease relationships based on miRNA-disease associations. This involved:

  • Data Curation: Collecting and curating miRNA-disease association data with tissue expression information from the HMDD database.
  • Disease Vector Creation: Defining each disease as a vector where each dimension represents the strength of its association with a specific miRNA.
  • Disease Similarity Calculation: Employing the Tanimoto coefficient to calculate pairwise disease similarities, which accounts for both the direction and weight of miRNA associations, and also considers vector norms to mitigate research imbalance.
  • Network Construction: Building a miRNA-based disease network (MRDN) by connecting diseases with a similarity above a threshold of ±0.05.
  • Network Analysis: Investigating disease patterns, clustering, and coherence within the MRDN.
  • Drug Repurposing Hypothesis: Identifying potential drug candidates based on disease similarity.
  • In Vivo Validation: Testing the efficacy of a repurposed drug (methotrexate) in an elastase-induced AAA mouse model.

Datasets

The primary dataset used was the HMDD database (version 3.0), which contains manually curated experimental evidence for human miRNA-disease associations. This dataset was filtered to include associations with unambiguous tissue expression regulation information.

Key Insights and Ideas

  • AAA as an Autoimmune Disease: The most striking finding is that AAA exhibits the strongest similarity to autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, rather than other cardiovascular diseases. This suggests a potential autoimmune component in AAA's etiology.
  • Network Medicine for Drug Discovery: The study demonstrates the power of network medicine and miRNA-disease associations in uncovering non-obvious disease relationships and identifying potential therapeutic targets.
  • Methotrexate as a Promising Candidate: The strong similarity between AAA and autoimmune diseases directly led to the hypothesis that drugs used for autoimmune conditions could be effective for AAA. Methotrexate, a common drug for autoimmune diseases, emerged as a prime candidate.
  • Disease Network Coherence: The constructed MRDN showed a high degree of coherence in disease loops, indicating consistent relationships between diseases, which strengthens the reliability of the network's findings.

Key Results

  • A miRNA-derived disease network (MRDN) was constructed with 304 nodes (diseases) and 2,440 edges (1,521 positive, 919 negative).
  • AAA was found to be most similar to rheumatoid arthritis and systemic lupus erythematosus.
  • In animal experiments, methotrexate (MTX) administration significantly attenuated the formation and development of AAA.
  • MTX significantly reduced infrarenal aorta expansion and elastin degradation.
  • MTX markedly decreased macrophage infiltration in the aneurysmal wall.
  • A higher dose of MTX (25 mg/kg) showed a more pronounced therapeutic effect on AAA development and inflammation.
  • Hydroxychloroquine, another immunosuppressant, did not show significant therapeutic effects on AAA in the mouse model.

Limitations and Future Work

  • Data Incompleteness: The authors acknowledge that many diseases in their dataset were associated with only a few miRNAs, and some diseases were not linked at all, likely due to the incompleteness of current data.
  • Organ-Specific miRNA Information: The current miRNA-disease association data lacks organ distribution information, which could improve the accuracy of disease representation.
  • MiRNA Expression vs. Disease Processes: miRNA expression information may not fully capture all disease processes.
  • Mechanism of Action: The exact mechanism by which methotrexate acts on AAA is unknown and warrants further investigation, especially in comparison to its known mechanism in rheumatoid arthritis.
  • Multi-omics Integration: The authors suggest that integrating multi-omics data into network medicine could benefit future analyses.
  • Broader Applicability: The study's findings suggest that the developed algorithm is applicable to diseases beyond AAA, and further exploration of other disease categories is recommended.

Summary updated

Abstract

Abstract Abdominal aortic aneurysm (AAA) is a highly lethal vascular disease characterized by permanent dilatation of the abdominal aorta. The main purpose of the current study is to search for noninvasive medical therapies for abdominal aortic aneurysm (AAA), for which there is currently no effective drug therapy. Network medicine represents a cutting-edge technology, as analysis and modeling of disease networks can provide critical clues regarding the etiology of specific diseases and which therapeutics may be effective. Here, we proposed a novel algorithm to quantify disease relations based on a large accumulated microRNA-disease association dataset and then built a disease network that covered 15 disease classes and included 304 diseases. Analysis revealed a number of patterns for these diseases; for example, diseases tended to be clustered and coherent in the network. Surprisingly, we found that AAA showed the strongest similarity with rheumatoid arthritis and systemic lupus erythematosus, both of which are autoimmune diseases, suggesting that AAA could be one type of autoimmune disease in etiology. Based on this observation, we further hypothesized that drugs for autoimmune disease could be repurposed for the prevention and therapy of AAA. Finally, animal experiments confirmed that methotrexate, a drug for autoimmune disease, was able to prevent the formation and inhibit the development of AAA.
BibTeX
@misc{shen2021modeling,
  author = {Yicong Shen and Yuanxu Gao and Jiangcheng Shi and Zhou Huang and Rongbo Dai and Yi Fu and Yuan Zhou and Wei Kong and Qinghua Cui},
  title = {{Modeling of microRNA-derived disease network repurposes methotrexate for the prevention and therapy of abdominal aortic aneurysm in mice}},
  year = {2021},
  doi = {10.1101/2021.12.13.472366},
  howpublished = {bioRxiv},
}
Figure